DN-R175H p53 mutation is more effective than p53 interference in inducing epithelial disorganization and activation of proliferation signals in human carcinoma cells: Role of E-cadherin

International Journal of Cancer

Volumn 125, Issue 7, 2009, Pages 1604-1612

  Rieber, Manuel ^a   Rieber, Mary Strasberg ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

E cadherin; EGF receptor erbB1; Laser scanning cytometry; MMP 9

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; MUTANT PROTEIN; PIFITHRIN ALPHA; PROTEIN P53; UVOMORULIN;

ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOARCHITECTURE; DOWN REGULATION; EPITHELIUM; GENE DISRUPTION; GENE FUNCTION; GENE MUTATION; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STABLE TRANSFECTION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ARGININE; BREAST NEOPLASMS; CADHERINS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN A; DOWN-REGULATION; EPITHELIAL CELLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; GENES, ERBB-1; HISTIDINE; HUMANS; IMMUNOBLOTTING; LASER SCANNING CYTOMETRY; MATRIX METALLOPROTEINASE 9; MUTATION; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROVIRIDAE; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 68549086989     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24512     Document Type: Article

References (42)

1. Vogelstein B, Lane D, Levine A. Surfing the p53 network. Nature 2000;408:307-10.
2. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-61.
3. Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, Ohuchi N, Ishioka C. Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci 2008;99:324-32.
4. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-65.
5. Khalil MY, Grandis JR, Shin DM. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 2003;3:367-80.
6. Modi S, D'Andrea G, Norton L, Yao TJ, Caravelli J, Rosen PP, Hudis C, Seidman AD. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006;7:270-7.
7. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P, Love S, Scott WN, Williams AR, Lessells AM, MacLeod KG, Smyth JF, et al. The prognostic value of epidermal growth factor mRNA expression in primary ovarian cancer. Br J Cancer 1996;73:301-6.
8. Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, DiGiovanni J. Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res 2004;64:2382-9.
9. Herbst RS, Onn A, Mendelsohn J. The role of growth factor signaling in malignancy. Cancer Treat Res 2003;115:19-72.
10. Rittié L, Kansra S, Stoll SW, Li Y, Gudjonsson JE, Shao Y, Michael LE, Fisher GJ, Johnson TM, Elder JT. Differential ErbB1 Signaling in squamous cell versus basal cell carcinoma of the skin. Am J Pathol 2007;170:2089-99.
11. Yoon KS, Lee MC, Kang SS, Kim JH, Jung S, Kim YJ, Lee JH, Ahn KY, Lee JS, Cheon JY. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma. J Korean Med Sci 2001;16:481-8.
12. Sehgal G, Hua J, Bernhard EJ, Sehgal I, Thompson TC, Muschel RJ. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol 1998;152:591-6.
13. Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, Uehira M. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 1999;17:177-81.
14. Ellerbroek SM, Hudson LG, Stack MS. Proteinase requirements of epidermal growth factor induced ovarian cancer cell invasion. Int J Cancer 1998;78:331-7.
15. Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, Stack MS, Hudson LG. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 2001;61:1855-61.
16. Cowden Dahl KD, Symowicz J, Ning Y, Gutierrez E, Fishman DA, Adley BP, Stack MS, Hudson LG. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells. Cancer Res 2008;68:4606-13.
17. Fish EM, Molitoris BA. Alterations in epithelial polarity and the pathogenesis of disease states. N Engl J Med 1994;330:1580-8.
18. Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 2001;3:289-93.
19. Hazan RB, Norton L. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 1998;273:9078-84.
20. Gadea G, de Toledo M, Anguille C, Roux P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol 2007;178:23-30.
21. Thiery JP. Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2002;2:442-54.
22. Borresen AL, Andersen TI, Eyford JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995;14:71-5.
23. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733-7.
24. Murphy PJ, Galigniana MD, Morishima Y, Harrell JM, Kwok RP, Ljungman M, Pratt WB. Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J Biol Chem 2004;279:30195-201.
25. Rieber M, Medina JD, Strasberg Rieber M. Relationship of Mcl-1 isoforms, ratio p21WAF1/cyclin A, and Jun kinase phosphorylation to apoptosis in human breast carcinomas. Biochem Biophys Res Comm 2002;297:943-9.
26. Strasberg Rieber M, Zangemeister-Wittke U, Rieber M. p53-dependent induction of apoptosis in human melanoma cells by a bcl-2/bclxL bispecific antisense oligonucleotide. Clin Cancer Res 2001;7:1446-51.
27. Serrano M, Lin AW, McCurrach M, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
28. Strasberg Rieber M, Anzellotti A, Sanchez-Delgado R, Rieber M. Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor. Int J Cancer 2004;112:376-84.
29. Ozcelik H, Mousses S, Andrulis IL. Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations. Clin Cancer Res 1995;1:907-12.
30. Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J, van Diest P. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 2002;86:402-8.
31. Bukholm IR, Bukholm G, Nesland JM. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 2001;93:283-7.
32. Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A, Valerie K, Deb SP, Deb S. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 2004;23:4430-43.
33. Kobayashi T, Hashimoto K, Okumura H, Asada H, Yoshikawa K. Endogenous EGF-family growth factors are necessary for the progression from the G1 to S phase in human keratinocytes. J Invest Dermatol 1998;11:616-20.
34. Gloushankova1 N, Ossovskaya V, Vasiliev J, Chumakov P, Kopnin B. Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes. Oncogene 1997;15:2985-9.
35. Gadéa G, Lapasset L, Gauthier-Rouviere C, Roux P. Regulation of Cdc42-mediated morphological effects: a novel function for p53. EMBO J 2002;21:2373-82.
36. Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Vanveldhuizen PJ, Banerjee SK. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res 2008;68:4580-7.
37. Helguero LA, Lindberg K, Gardmo C, Schwend T, Gustafsson JA, Haldosén LA. Different roles of estrogen receptors alpha and beta in the regulation of E-cadherin protein levels in a mouse mammary epithelial cell line. Cancer Res 2008;68:8695-104.
38. Fouquet S, Lugo-Martínez VH, Faussat AM, Renaud F, Cardot P, Chambaz J, Pinçon-Raymond M, Thenet S. Early loss of E-cadherin from cell-cell contacts is involved in the onset of anoikis in enterocytes. J Biol Chem 2004;279:43061-9.
39. Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, Kotilingam D, Yu D, Lazar AF, Pollock RE, Lev D. Wild-type p53 inhibits nuclear factor-κκb- induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res 2006;4:803-10.
40. Done SJ, Arneson CR, Ozcelik H, Redston M, Andrulis IL. p53 accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers. Breast Cancer Res Treat 2001;65:111-18.
41. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000;60:2155-62.
42. Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, et al. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res 2003;9:1253-8.